Patents by Inventor Tanya Momtahen

Tanya Momtahen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230127528
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Application
    Filed: September 22, 2022
    Publication date: April 27, 2023
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Patent number: 11498969
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: November 15, 2022
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Publication number: 20200339693
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Application
    Filed: January 31, 2020
    Publication date: October 29, 2020
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Patent number: 5859007
    Abstract: Benzo?b!?1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: January 12, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Christopher Joseph Aquino, Marcus Brackeen, Milana Dezube, Brad Richard Henke, Gavin Charles Hirst, Peter Walter Jeffs, Tanya Momtahen, Elizabeth Ellen Sugg, Edward Martin Suh, Timothy Mark Willson